Associations between vitamin D status and type 2 diabetes measures among Inuit in Greenland may be affected by other factors by Nielsen, Nina O et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Associations between vitamin D status and type 2 diabetes measures among Inuit in
Greenland may be affected by other factors
Nielsen, Nina O; Bjerregaard, Peter; Rønn, Pernille F; Friis, Henrik; Andersen, Stig; Melbye,
Mads; Lundqvist, Marika; Cohen, Arieh S; Hougaard, David M; Jørgensen, Marit E
Published in:
P L o S One
DOI:
10.1371/journal.pone.0152763
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Nielsen, N. O., Bjerregaard, P., Rønn, P. F., Friis, H., Andersen, S., Melbye, M., ... Jørgensen, M. E. (2016).
Associations between vitamin D status and type 2 diabetes measures among Inuit in Greenland may be affected
by other factors. P L o S One, 11(4), [e0152763]. https://doi.org/10.1371/journal.pone.0152763
Download date: 03. Feb. 2020
RESEARCH ARTICLE
Associations between Vitamin D Status and
Type 2 Diabetes Measures among Inuit in
Greenland May Be Affected by Other Factors
Nina O. Nielsen1*, Peter Bjerregaard1,2, Pernille F. Rønn3,4, Henrik Friis5, Stig Andersen6,
Mads Melbye7, Marika Lundqvist8, Arieh S. Cohen8, David M. Hougaard8, Marit
E. Jørgensen3,1
1 National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark, 2 Greeenland
Centre for Health Research, University of Greenland, Nuuk, Greenland, 3 Steno Diabetes Centre, Gentofte,
Denmark, 4 Department of Public Health, Aarhus University, Aarhus, Denmark, 5 Department of Nutrition,
Exercise and Sports, University of Copenhagen, Copenhagen, Denmark, 6 Aalborg University Hospital,
Aalborg, Denmark, 7 Department of Epidemiology Research, Statens Serum Institut, Copenhagen,
Denmark, 8 Department of Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark
* noni@niph.dk
Abstract
Objective
Epidemiological studies have provided evidence of an association between vitamin D insuf-
ficiency and type 2 diabetes. Vitamin D levels have decreased among Inuit in Greenland,
and type 2 diabetes is increasing. We hypothesized that the decline in vitamin D could have
contributed to the increase in type 2 diabetes, and therefore investigated associations
between serum 25(OH)D3 as a measure of vitamin D status and glucose homeostasis and
glucose intolerance in an adult Inuit population.
Methods
2877 Inuit (18 years) randomly selected for participation in the Inuit Health in Transition
study were included. Fasting- and 2hour plasma glucose and insulin, C-peptide and HbA1c
were measured, and associations with serum 25(OH)D3 were analysed using linear and
logistic regression. A subsample of 330 individuals who also donated a blood sample in
1987, were furthermore included.
Results
After adjustment, increasing serum 25(OH)D3 (per 10 nmol/L) was associated with higher
fasting plasma glucose (0.02 mmol/L, p = 0.004), 2hour plasma glucose (0.05 nmol/L, p =
0.002) and HbA1c (0.39%, p<0.001), and with lower beta-cell function (-1.00 mmol/L,
p<0.001). Serum 25(OH)D3 was positively associated with impaired fasting glycaemia (OR:
1.08, p = 0.001), but not with IGT or type 2 diabetes.
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Conclusions
Our results did not support an association between low vitamin D levels and risk of type 2
diabetes. Instead, we found weak positive associations between vitamin D levels and fast-
ing- and 2hour plasma glucose levels, HbA1c and impaired fasting glycaemia, and a nega-
tive association with beta-cell function, underlining the need for determination of the causal
relationship.
Introduction
Previously, low vitamin D was mainly a concern in relation to calcium homeostasis, and defi-
ciency could cause the bone-deforming rickets disease in children and lead to the development
of osteoporosis and osteomalacia in adults. However, during the last decades epidemiological
evidence from various parts of the world has linked low vitamin D levels with metabolic and
cardiovascular disorders, infectious and inflammatory diseases, and some cancer types [1–2],
indicating a broader role of vitamin D in human health. Associations between low vitamin D
status and type 2 diabetes have been reported in several cross-sectional studies [3, 4], as well as
prospective cohort studies [5–7]. Two recent large prospective cohort studies provided evi-
dence of an inverse association between serum 25-hydroxyvitamin D (25(OH)D) and markers
of glucose homeostasis [6] and risk of type 2 diabetes [7], indicating a causal relationship. In
contrast, some studies have reported lack of association between 25(OH)D levels and incident
type 2 diabetes [8], and Mendelian randomization studies and randomized placebo-controlled
trials have questioned a causal association between vitamin D and type 2 diabetes [9, 10]. Dif-
ferent methods and designs have been used in these studies. Some have measured the dietary
intake of vitamin D, which does not account for the large proportion synthesized in the skin
[11, 12], whereas others have used blood 25-hydroxyvitamin D (25(OH)D) as a biomarker of
vitamin D status [8]. Furthermore, the recording of diabetes varies among self-report [8], med-
ication registry data [13] and diagnosis based on blood glucose levels [6].
In most areas of the world dermal production of vitamin D from exposure to sunlight is the
main source of vitamin D. However, high latitude populations (above 40°N) are incapable of
producing sufficient amounts of vitamin D in the winter months, and during this period of the
year diet is the main source. As part of the Arctic region, Greenland is located at very high lati-
tudes (60°N–78°N). The Inuit population therefore experiences extended periods of darkness,
and even in the periods where sunlight is present, vitamin D synthesis is limited due to the
high solar zenith angle [14] and the continued need for outdoor clothing [15]. Consequently,
dietary vitamin D is crucial to this population. Previously, the traditional diet containing fish
and sea mammals probably maintained a healthy vitamin D status among the Inuit [16]. How-
ever, as a result of the extensive nutrition transition which has occurred in Greenland during
the past 50–60 years, the traditional diet has to a large extent been substituted by imported
foods such as fatty meat, sweets, chips, cakes and soft drinks. We recently reported a profound
decrease in vitamin D status from 1987 to 2010, due to a change away from a traditional diet
[17].
In this study, we aimed to examine the association between vitamin D and glucose homeo-
stasis and glucose intolerance in the same Inuit population. Our study population is particu-
larly appropriate for this purpose due to the low vitamin D status and increasing prevalence of
type 2 diabetes; the current prevalence is 7–10% among adults [18, 19]. Furthermore, we have a
subsample of the study population with data on vitamin D status in 1987, which allows
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analyses of associations between former vitamin D status and later development of type 2 dia-
betes. We hypothesised that low vitamin D levels were associated with higher risk of type 2 dia-
betes. Serum 25-hydroxyvitamin D3 (25(OH)D3) concentration was used as a measure of
vitamin D status, and HbA1c and fasting- and 2hour plasma glucose and insulin levels were
used as measures of glucose homeostasis and glucose intolerance.
Methods
Study participants and design
The total population of Greenland is 57.000, and approximately 90% of the population is indig-
enous Greenlanders (Inuit), while the remaining are mainly Danes. The population inhabits
16 towns and approximately 60 villages. Study participants were part of a general health study
among adults (all age groups18 years) in Greenland established in 2005–2010 (Inuit Health
in Transition (IHIT) study) [20]. Participants in the main health study were selected through a
random sampling of adults with permanent residence in Greenland. Greenland was divided into
twelve regions, and from each region a number of villages and towns were chosen to be included
in the study. Twenty-two communities, including the capital Nuuk, eight smaller towns, and 13
villages were selected as study areas being representative of each region in Greenland [20, 21]. In
villages, all adult inhabitants were invited to participate, whereas in towns, a random sample of
11–22% was drawn from the central population register. With a participation rate for Inuit of
68%, the total study sample consisted of 3108 Inuit (9.1% of the total adult population in 2005)
representing all geographical areas and community sizes. Categorization as Inuit was based on
the primary language and self-identification. From 2877 (93%), a serum 25(OH)D3measure-
ment was obtained, which was included in this cross-sectional study. Before analyses of associa-
tions, non-fasting individuals and individuals with previously diagnosed diabetes were excluded
(n = 144). Among individuals with a serum 25(OH)D3 measurement, 485 individuals had
donated a blood sample as part of their participation in a population-based serological syphilis
survey carried out in 1987 in western and southern districts of Greenland [22]. The syphilis
screening, and treatment, was carried out following an epidemic in April 1987 and was offered to
all individuals aged 15–60 years; the 485 individuals represented inhabitants of Aasiaat, Maniit-
soq, Qaqortoq, and Narsaq. From 330 of these, a blood sample was stored and available for mea-
surement of 25(OH)D3. These historical samples allowed the assessment of associations between
past serum 25(OH)D3 levels and future glucose metabolism.
Collection and handling of blood samples
Blood samples from 1987 were drawn fromMay to June, whereas samples from 2005–2010
were collected during all months of the year in the period April 2005 to October 2010, except
for July, November and December (due to annual leave and inaccessibility). Samples from
2005–2010 were collected as part of the IHIT study in nine towns and 13 villages by expedi-
tions along the north-west, south and the east coasts of Greenland. Blood samples were han-
dled and stored as described elsewhere [17].
Insulin and glucose measures
Fasting blood samples were drawn from individuals who had spent a minimum of eight hours
without consuming any food or liquids. Participants underwent a 2hour OGTT, in which they
received 75 g of glucose, and another blood sample was taken. Plasma glucose was analyzed
using Hexokinase/G6P-DH-Determiation on a Hitachi 912 System. Insulin measures were
analyzed by two-site fluoroimmunometric assay for quantification of intact insulin in human
Vitamin D and Type 2 Diabetes in Greenland
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serum (Wallac Auto Delfia). C-peptide was measured in pmol/L in serum, which was allowed
to rest for 30–150 minutes before centrifugation at 20°C, 3000 rpm for 10 minutes. After cen-
trifugation, the C-peptide samples were frozen at -20°C. C-peptide was analysed by Immunoas-
say for the in vitro quantitative determination of C-peptide in human plasma using Cobas
e411, Roche. HbA1c was taken in a capillary tube and analyzed by the principles of an ion-
exchange HPLC Bio-Rad variant (Hercules, California) as described elsewhere [23]. Samples
were kept refrigerated until analysis of HbA1c. All measurements were performed at the Steno
Diabetes Centre, Gentofte, Denmark. Hepatic insulin resistance (HOMA-IR) was calculated as
fasting insulin (pmol/L)  fasting plasma glucose (mmol/L)/22.5. The Insulin sensitivity index
(ISI0,120) was calculated according to Gutt el al. [24] to provide an estimate of insulin sensitivity
in the peripheral tissues as follows:
ISI0;120 ¼ ½75; 000þ ðfasting glucose 18  2hour glucose 18Þ  0:19 body weight ðkgÞ ∕ 120 min
ðfasting glucoseþ 2hour glucoseÞ ∕ 2
∕ log ðfasting insulin ∕ 6:945Þ þ ð2hour insulin ∕ 6:945Þ ∕ 2
As a measure of beta-cell function the fasting C-peptide/fasting insulin ratio was calculated.
According to the current WHO-guidelines [25], impaired fasting glycaemia (IFG), impaired
glucose tolerance (IGT), and type 2 diabetes were deﬁned as follows: IFG = fasting plasma
glucose 6.1 to 6.9 mmol/L and 2hour plasma glucose< 7.8 mmol/L, IGT = fasting plasma
glucose< 7.0 mmol/L and 2hour plasma glucose 7.8 and< 11.1 mmol/L, type 2 diabetes =
fasting plasma glucose 7.0 mmol/L or 2hour plasma glucose 11.1 mmol/L, and/or a history
of type 2 diabetes.
Vitamin D measurements
IHIT samples were stored for 3–7 years and the 1987-samples for 26 years at -80°C before
thawn and analyzed for 25(OH)D3 and 25(OH)D2. Analyses were performed by liquid chro-
matography-tandem mass spectrometry (LC-MSMS) using the “MSMS vitamin D” kit from
Perkin Elmer (Waltham, MA) as described previously [26]. This method measured both serum
25(OH)D3 and 25(OH)D2, but due to the negligible 25(OH)D2 concentrations detected, only
25(OH)D3 was considered in the analyses.
Potential confounders
In connection with blood sample collections in the IHIT study, information on potential con-
founders was obtained. Data on ancestry (fully or partly Inuit), smoking, physical activity energy
expenditure, and use of supplements (vitamin D and multivitamins) were collected by interview-
guided questionnaires. Ancestry was based on the grandparent’s ethnicity. A participant with
four Inuit grandparents was defined as fully Inuit, whereas a participant with 1–3 grandparents
of non-Inuit descent was defined as partly Inuit. Physical activity was recorded by the Interna-
tional Physical Activity Questionnaire (long version IPAQ) validated and modified for the living
conditions of the Greenlandic population [27]. Anthropometric measurements were used to cal-
culate body mass index (BMI) as: ((weight in kg)/(height in m)2). Data on total blood mercury
levels were obtained frommeasurements in serum samples. Information on potential confound-
ers beyond age and sex was not available from the 1987-sample.
Ethics
Participants in the IHIT-study gave their informed written consent to participate in health
investigations at inclusion in the study. The present study, including use of the stored samples
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from 1987, was reviewed and approved by the Ethical Review Committee for Greenland. The
samples from 1987 are from a population-based serological syphilis survey [21] and were
stored at The Danish National Biobank, Statens Serum Institut, Copenhagen, Denmark (http://
www.ssi.dk/English/Service/AboutSSI/Organization/Organisationchart/Department.aspx?id=
e4091b0d-0269-4445-9fe5-9db500a0483e) from where they were procured. Since all study par-
ticipants gave their informed written consent to participate in the IHIT-study in 2005–2010,
the Ethical Review Committee for Greenland waived the need for consent regarding the sam-
ples previously collected from the same individuals in 1987.
Statistical methods
The statistical analyses were performed in STATA 12 and SAS 9.3 (SAS Institute Inc., Carey,
NC, USA). All continuous outcome variables, except fasting plasma glucose and 2hour plasma
glucose, were transformed using the natural logarithm function to obtain normal distributions
before entered in linear regression models. Transformed coefficients were back-transformed
and expressed as percentage change per 10 nmol/L increase in serum 25(OH)D3. Associations
between serum 25(OH)D3 levels and fasting plasma glucose and 2hour plasma glucose were
expressed as change in units (mmol/L) per 10 nmol/L increase in serum 25(OH)D3. We tested
for non-linearity by inclusion of a quadratic term of serum 25(OH)D3. Since a borderline sig-
nificant non-linear relation was observed between 25(OH)D3 and HbA1c, we used multiple
regression with quadratic splines to visually investigate the relation, with 25(OH)D3 as explan-
atory variable and HbA1c as outcome variable. The spline was interpolated with four knots
placed at 40 nmol/L, 80 nmol/L, 120 nmol/L and 160 nmol/L on the 25(OH)D3 scale. We pre-
dicted values for a man with prespecified values of the covariates (44 years, smoker, fully Inuit,
BMI of 26 kg/m2 and physical activity energy expenditure of 46 kJ/kg/day). We tested for lin-
earity by comparing the spline model with a model with linear effect of 25(OH)D3.
Associations between serum 25(OH)D3 and categorical outcome variables (IFG, IGT and
type 2 diabetes) were assessed by logistic regression models.
Results
Characteristics of the study population
Of the 330 participants in the 1987-sample and the 2877 individuals in the IHIT study (2005–
2010) with data on serum 25(OH)D3, 319 (97%) and 2566 (89%), respectively, had complete
data on all outcome variables and selected confounders. The median age (interquartile range,
IQR) of the 1987-sample and the IHIT-sample was 31 (IQR: 23–40) years and 44 (IQR: 34–54)
years, respectively. The median (IQR) serum 25(OH)D3 was 59.0 (IQR: 38.3–90.5) nmol/L in
the 1987-sample and 46.6 (IQR: 29.7–67.4) nmol/L in the IHIT-sample, and the respective pro-
portions of men in the two study populations were 41% and 44%.
Table 1 gives characteristics of the study population in 1987 and 2005–2010 by sex. Median
serum 25(OH)D3 was higher among men than women in 1987 (64 vs. 57 nmol/L), but did not
differ between men and women in 2005–2010 (49 vs. 45 nmol/L). Median BMI was remarkably
high among both men and women, but higher among women (25 vs. 26 kg/m2), whereas the
level of physical activity energy expenditure (52 vs. 46 kJ/kg/day) and total blood mercury
(19 vs. 14 μg/L) were higher among men. Fasting plasma glucose and HbA1c were also higher
among men, whereas 2hour plasma glucose and fasting- and 2hour insulin were higher among
women. Overall, the prevalence of IFG, IGT, and type 2 diabetes was 13%, 5.3% and 8.8%,
respectively. IFG was more prevalent among men than women (16% vs. 11%), whereas IGT
was more prevalent among women than men (6.8% vs. 3.2%). The prevalence of type 2 diabetes
was not different among men and women (10% vs. 8%).
Vitamin D and Type 2 Diabetes in Greenland
PLOS ONE | DOI:10.1371/journal.pone.0152763 April 13, 2016 5 / 13
Associations with glucose homeostasis
Overall, there was no interaction between sex and the association between serum 25(OH)D3
and markers of glucose homeostasis. Analyses were therefore performed for men and women
together.
Table 2 shows the association between serum 25(OH)D3 measured in the IHIT-study in
2005–2010 and markers of glucose homeostasis measured in the same investigation before and
after adjustment for potential confounders. After adjustment for sex, age, ancestry, BMI, smok-
ing, physical activity, and supplementation with vitamin D or multivitamins (Model 2),
increasing 25(OH)D3, expressed per 10 nmol/L, was associated with increasing fasting plasma
glucose (0.03 mmol/L, 95% CI: 0.02; 0.04), 2hour plasma glucose (0.06 mmol/L, CI: 0.03; 0.09)
and HbA1c (0.51%, 95% CI: 0.37%; 0.66%). In contrast, increasing 25(OH)D3 levels were asso-
ciated with decreasing beta-cell function (-0.82%, CI: -1.30; -0.33). No association with periph-
eral insulin sensitivity (ISI0,120) and HOMA-IR was found after adjustment for confounders. In
Model 3, the associations between 25(OH)D3 and glucose homeostasis measures were addi-
tionally adjusted for total blood methyl mercury concentrations after assessment of sufficient
variation in the relation between 25(OH)D3 and mercury. After full adjustment, the weak
positive association with fasting plasma glucose (0.02 mmol/L; CI: 0.01; 0.03), 2hour plasma
glucose (0.05 mmol/L, CI: 0.02; 0.08) and HbA1c (0.39%, 95% CI: 0.23%; 0.54%) remained sig-
nificant, and the inverse association with beta-cell function also persisted (-1.00%; CI: -1.52;
-0.47).
Table 1. Characteristics of the study population in 1987 (N = 330) and 2005–2010 (N = 2877).
1987 n Men n Women
Age (years) 134 33 (24–41) 196 29 (22–39)
25(OH)D3 (nmol/L)* 134 64 (39–103) 196 57 (36–82)
2005–2010 n Men n Women
Age (years) 1256 45 (35–55) 1621 43 (33–53)
BMI (kg/m2) 1241 25 (22–29) 1609 26 (23–30)
25(OH)D3 (nmol/L) † 1256 49 (29–70) 1621 45 (30–66)
Physical activity energy expenditure (kJ/kg/day) 1254 52 (23–97) 1620 46 (24–74)
Fasting plasma glucose (mmol/L) 1242 5.7 (5.3–6.1) 1606 5.5 (5.2–5.9)
2hour plasma glucose (mmol/L) 1202 5.0 (4.0–6.4) 1545 5.7 (4.7–7.0)
Fasting insulin (pmol/L) 1243 33 (22–50) 1606 42 (29–61)
2hour insulin (pmol/L) 1202 63 (30–142) 1544 148 (80–249)
HbA1C (mmol/mol) 1250 39 (37–41) 1617 38 (36–41)
HbA1C (%) 1250 5.7 (5.5–5.9) 1617 5.6 (5.4–5.9)
Mercury (μg/L) 1254 19 (8.2–42) 1617 14 (6.6–32)
Supplementation‡ 1256 8.2 (103) 1621 12.8 (207)
Ancestry, % fully Inuit (n) 1241 86 (1071) 1600 88 (1407)
Smokers, % (n) 1254 66 (825) 1617 69 (1123)
IFG, % (n) 1217 16 (189) 1566 11 (169)
IGT, % (n) 1217 3.2 (39) 1566 6.8 (107)
IFG+IGT, % (n) 1217 3.0 (36) 1566 3.5 (55)
Type 2 diabetes, % (n) 1217 10 (116) 1566 8 (128)
Data are median (interquartile range) unless otherwise stated.
* Median concentration in May-June 1987.
† Median concentration in all months except July, November and December 2005–2010.
‡Vitamin D or multivitamins.
doi:10.1371/journal.pone.0152763.t001
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Due to a borderline significant quadratic term of serum 25(OH)D3 in relation to HbA1c,
indicating a non-linear association, we investigated this association further with spline analyses
(Fig 1). The shape of the association between 25(OH)D3 and HbA1c did not vary much from a
linear association, and a statistical test likewise indicated no deviation from linearity (p = 0.26).
When using 25(OH)D3 levels measured in samples from 1987 as a predictor of the glucose
homeostasis outcomes measured in 2005–2010, increasing 25(OH)D3 concentrations were
associated with increasing HbA1c (0.46%, 95% CI: 0.26%; 0.65%) and peripheral insulin sensi-
tivity (2.09%, 95% CI: 0.26%; 3.96%) after adjustment for age and sex, whereas no associations
with fasting- and 2hour plasma glucose, beta-cell function and HOMA-IR, were found.
Associations with glucose intolerance
Table 3 gives the unadjusted and adjusted associations between serum 25(OH)D3 and IFG,
IGT and type 2 diabetes in 2005–2010. In Model 1 and 2 the estimates indicated a positive asso-
ciation with IFG and type 2 diabetes. For each 10 nmol/L increase in serum 25(OH)D3, the
adjusted odds of IFG increased by 10% (OR: 1.10, CI: 1.06; 1.14), and by 7% (OR: 1.07, CI:
1.01; 1.12) for type 2 diabetes after adjustment for confounders, whereas no association with
IGT was observed. In Model 3, the associations with IFG remained significant (OR: 1.08, CI:
1.03; 1.12), whereas the association with type 2 diabetes disappeared after additional adjust-
ment for mercury. Serum 25(OH)D3 measured in 1987 was not associated with IFG (OR: 1.08,
CI: 0.99; 1.17; n = 260), IGT (OR: 0.99, CI: 0.86; 1.13; n = 241) or type 2 diabetes (OR: 0.99, CI:
0.88; 1.11; n = 321) as defined in 2005–2010 after adjustment for age and sex. The number of
cases with IFG, IGT and type 2 diabetes among the participants with a serum 25(OH)D3 mea-
surement from 1987 was 41 (12.4%), 22 (6.7%), 33 (10.0%), respectively.
Discussion
Based on the existing literature, we expected to find an inverse linear or a non-linear (i.e.
U-shaped or reverse J-shaped) association between 25(OH)D3 levels and markers of glucose
Table 2. Association between serum 25(OH)D3 (nmol/L) andmeasures of glucose homeostasis in 2005–2010.
Model 1 Model 2 Model 3
Unadjusted model Adjusted for sex, age, ancestry
(Inuit or partly Inuit), BMI,
smoking, physical activity, and
supplementation*
Additionally adjusted for total
blood mercury
n Change (95% CI) P-value n Change (95% CI) P-value n Change (95% CI) P-value
Association with 25(OH)D3
Fasting plasma glucose 2733 0.11 (0.08; 0.14) <0.001 2580 0.03 (0.02; 0.04) <0.001 2577 0.02 (0.01; 0.03) 0.004
2hour plasma glucose 2720 0.23 (0.14; 0.31) <0.001 2570 0.06 (0.03; 0.09) <0.001 2567 0.05 (0.02; 0.08) 0.002
Peripheral insulin sensitivity
(ISI 0,120)
2693 -3.92 (-5.84;
-1.96)
<0.001 2569 -0.24 (-0.90; 0.43) 0.49 2566 -0.38 (-1.10; 0.34) 0.30
Fasting c-peptide/fasting insulin
ratio
2733 0.82 (0.33; 1.31) 0.001 2580 -0.82 (-1.30;
-0.33)
0.001 2577 -1.00 (-1.52;
-0.47)
<0.001
HOMA-IR 2733 0.93 (-1.42; 3.33) 0.44 2580 -0.37 (-1.10; 0.36) 0.33 2577 -0.34 (-1.12; 0.46) 0.41
HbA1c 2723 2.08 (1.67; 2.49) <0.001 2570 0.51 (0.37; 0.66) <0.001 2567 0.39 (0.23; 0.54) <0.001
Associations are expressed as change in units (for fasting plasma glucose and 2hour plasma glucose) or percent change (for ln-transformed outcomes)
with 95% conﬁdence intervals per 10 nmol/L increase in 25(OH)D3. Only fasting individuals with newly diagnosed glucose intolerance were included in the
analyses.
*Vitamin D or multivitamins.
doi:10.1371/journal.pone.0152763.t002
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homeostasis and a negative association with glucose intolerance [2, 11, 28–30]. Surprisingly,
we found that increasing concentrations of serum 25(OH)D3 were associated with increasing
fasting plasma glucose, 2hour plasma glucose and HbA1c and decreasing beta-cell function
after adjustment for sex, age, ancestry, BMI, smoking, physical activity, and supplementation
Fig 1. Relation between serum 25(OH)D3 and HbA1c.Quadratic spline analysis showing the relation
between serum 25(OH)D3 concentrations and HbA1c for a man aged 44 years, being full Inuit and smoker,
and with a BMI of 26 kg/m2 and a physical activity energy expenditure of 46 kJ/kg/day. The thick line
represents the relation predicted, the full thin lines show the 95% confidence interval, and dotted lines show
the 95% prediction interval. N = 2355.
doi:10.1371/journal.pone.0152763.g001
Table 3. Association between serum 25(OH)D3 (nmol/L) and glucose intolerance in 2005–2010.
Model 1 Model 2 Model 3
Unadjusted model Adjusted for sex, age, ancestry
(Inuit or partly Inuit), BMI,
smoking, physical activity, and
supplementation§
Additionally adjusted for total
blood mercury
n OR (95% CI) P-value n OR (95% CI) P-value n OR (95% CI) P-value
Association with 25(OH)D3
IFG* 2302 1.16 (1.12; 1.19) <0.001 2175 1.10 (1.06; 1.14) <0.001 2172 1.08 (1.03; 1.12) 0.001
IGT† 2090 1.06 (1.01; 1.11) 0.03 1979 0.98 (0.91; 1.05) 0.62 1977 0.98 (0.91; 1.06) 0.63
Type 2 diabetes‡ 2733 1.30 (1.15; 1.45) <0.001 2580 1.07 (1.01; 1.12) 0.01 2577 1.04 (0.98; 1.09) 0.16
Associations are expressed as odds ratios (OR) with 95% conﬁdence intervals (CI) per 10 nmol/L increase in 25(OH)D3. Only fasting individuals with
newly diagnosed glucose intolerance were included in the analyses.
* IFG versus normal glucose tolerance.
† IGT versus normal glucose tolerance.
‡Type 2 diabetes versus normal glucose tolerance, IFG, IGT and IFG+IGT.
§Vitamin D or multivitamins.
doi:10.1371/journal.pone.0152763.t003
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with vitamin D or multivitamins. Furthermore, the odds of IFG and type 2 diabetes increased
with increasing vitamin D. After additional adjustment for mercury concentrations the associa-
tions remained significant, except for type 2 diabetes. The finding of serum 25(OH)D3 levels
measured in 1987 also being positively associated with HbA1c gives further support to the
observed association, although the estimates here were only adjusted for age and sex.
Interpreting these association patterns as a possible adverse effect of vitamin D on the
underlying mechanisms of type 2 diabetes would be in contrast to the several lines of evidence
supporting a favorable role for vitamin D in glucose homeostasis, including beneficial effects
on pancreatic beta-cell function and insulin action [31]. Vitamin D appears to affect the insulin
response to glucose stimulation directly by binding of the active form of vitamin D, 1,25(OH)
2D, to the vitamin D receptors on beta-cells [31]. Furthermore, 1,25(OH)2D activates tran-
scription of the human insulin receptor gene [32], stimulates the expression of insulin receptor,
and enhances insulin-mediated glucose transport [33]. Insulin secretion is a calcium dependent
process, and indirect effects of vitamin D may be mediated through its important role in regu-
lating extracellular calcium and calcium flux through the beta-cell [31]. In support of these
findings, prospective studies have shown a protective effect of high 25(OH)D concentrations
on type 2 diabetes risk [13, 28]. However, extremely high concentrations of vitamin D, which
may occur as a result of excessive supplemental intake, can be toxic and have adverse health
effects [34]. The highest concentration of 25(OH)D3 measured in this study (255 nmol/L) is
far below the level generally regarded as unfavorable or toxic (500 nmol/L) to human health
[34]. We therefore find it most plausible that the observed positive associations with fasting-
and 2hour plasma glucose and HbA1c in our study are carried by one or more other factors
associated with development of glucose intolerance and type 2 diabetes. Among such factors
could be environmental contaminants. We adjusted for methyl mercury because we recently
found a positive association between mercury and fasting- and 2hour plasma glucose, impaired
fasting glucose and type 2 diabetes in the same study population [35]. However, even after
adjustment for mercury, we found positive associations between 25(OH)D3 and glucose mea-
sures. Vitamin D is a strong marker of the intake of the traditional marine diet known to pro-
vide high levels of other types of environmental contaminants not accounted for here, and
these might influence the association between vitamin D and type 2 diabetes. Furthermore,
other micronutrients, such as phosphorus [36] and iron [37, 38], may affect the associations.
Alternatively, metabolism of vitamin D may play a role. In a study reporting an association
between high concentrations of vitamin D and increased risk of prostate cancer [39] the
authors suggested a role for 24-hydroxylase. This enzyme is stimulated by high concentrations
of plasma and intracellular 25(OH)D3 to rapidly hydroxylate vitamin D metabolites on carbon
24 to produce either inactive 24,25(OH)D or degrade the active form of vitamin D, 1,25(OH)
2D3, to the inactive 1,24,25-trihydroxyvitamin D3 metabolite. This will lower concentrations
of intracellular 1,25(OH)2D3 [39, 40], which could then allow increased proliferation of malig-
nant cells and hence an increased risk of prostate cancer. A similar 24-hydroxylase-based deg-
radation mechanism in response to high vitamin D concentrations may apply in type 2
diabetes. Low concentrations of 1,25(OH)2D resulting from degradation in response to high
25(OH)D3 concentrations, could be speculated to provide insufficient stimulation of vitamin
D receptors in beta-cells, resulting in impaired beta-cell function and impaired insulin secre-
tion [31], which in turn may result in elevated blood glucose levels. Adverse effects of low vita-
min D on beta-cell function has been documented previously [31]. Rapid degradation of 1,25
(OH)2D by 24-hydroxylase may have been beneficial in former generations in order to avoid
toxic vitamin D levels obtained from the traditional diet. Such rapid degradation may, however,
be unfavourable among present-day Inuit relying primarily on imported dietary sources with
lower content of vitamin D. The fact that a proportion of the study participants has a
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maintained high intake of traditional diet and a high serum 25(OH)D3 level, together with our
finding of a significant decrease in beta-cell function, may support the above hypothesis.
Regardless of the underlying mechanisms behind the weak positive associations between 25
(OH)D3 levels and glucose measures, these associations are considered of limited clinical
importance. With a modest increase in fasting- and 2hour plasma glucose of 0.02 mmol/L and
0.05 mmol/L, respectively, and 0.39% increase in HbA1c per 10 nmol/L increase in serum 25
(OH)D3 concentration, the contribution of lifestyle related risk factors such as smoking, physi-
cal inactivity and a diet containing high levels of saturated fat and sugar may affect glucose
homeostasis measures substantially more than vitamin D status. Moreover, a recent genome-
wide association study among Inuit in Greenland has discovered a frequent variant of the gene
TBC1D4 associated with type 2 diabetes, which has been estimated to account for more than
10 percent of all type 2 diabetes cases in Greenland [41]. Thus, genetic status is likely overruling
the role of vitamin D in this population. This is further supported by the lack of an association
between 25(OH)D3 and type 2 diabetes, and only a weak association with IFG, after adjust-
ment for mercury. Our findings may thus support the indications fromMendelian randomiza-
tion studies and randomized placebo-controlled trials that the association between 25(OH)D3
concentration and type 2 diabetes is unlikely to be causal (9, 10).
Serum 25(OH)D3 in 1987 and 2005–2010 was measured in blood samples stored for 3–26
years, which may introduce the risk of decay. However, higher contents of 25(OH)D3 in sam-
ples from 1987 than in 2005–2010 samples opposes this. Evaporation of the liquid part in the
test vial and thereby higher 25(OH)D3 concentration in the remaining serum, which could be
another concern, is unlikely to have occurred as sera were kept in vials with impervious lids
and wrapped in foil until thawing. Previous research has documented that the concentration of
25(OH)D3 appears to be stable in serum despite long storage periods [42] and exaggerated
conditions [43]. Thus, the reported serum 25(OH)D3 concentrations in samples from 1987
and 2005–2010 are likely to reflect the content at the time of sampling.
Strengths of the study included the use of serum 25(OH)D3 measurements from a large
stratified random sample of Inuit in Greenland with clinical measures of glucose homeostasis
and glucose intolerance. Furthermore, methyl mercury was measured, and detailed informa-
tion on sociodemographic and lifestyle conditions was available from questionnaires. By using
blood samples collected from a sub-sample of the IHIT study population in 1987 we were able
to estimate associations between serum 25(OH)D3 and markers of glucose homeostasis and
glucose intolerance in both 1987 and 2005–2010 allowing testing for robustness of association
patterns. While 1987 levels of 25(OH)D3 supported a positive association with HbA1c, there
was no association with fasting- and 2hour plasma glucose, beta-cell function, HOMA-IR, IFG,
IGT and type 2 diabetes, and the size of the estimate and the wide confidence limits for the
association with IFG indicated that the sample size was too small to detect a true association.
Thus, the lack of an association with IFG may be due to reduced power when using the serum
25(OH)D3 measurements from 1987. To further investigate the unexpected finding of a posi-
tive association between 25(OH)D3 and HbA1c, and the indication of non-linearity, we used
multiple regression with quadratic splines to visually investigate this relation. The graphical
presentation supported a positive linear relation between 25(OH)D3 and HbA1c. To exclude
the risk of reverse causality related to life style changes, only previously unknown diabetes and
pre-diabetes cases were included in the study. Among limitations of the study were the deter-
mination of serum 25(OH)D3 based on one measurement in the IHIT study, which may have
introduced measurement error, and over- and under-estimation of serum 25(OH)D3 status in
summer and winter seasons may have occurred due to the fact that samples were not available
from July, November and December. This is, however, unlikely to have affected the results.
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Another obvious limitation is the cross-sectional nature of the study which does not allow
determination of cause-effect relationships between exposure and outcome variables.
In conclusion, this large investigation undertaken in a randomly selected adult Inuit popula-
tion, found increasing serum 25(OH)D3 levels to be weakly associated with increased fasting-
and 2hour plasma glucose and HbA1c, increased odds of IFG, and decreased beta-cell function.
These findings are in contrast to some previous reports of favorable effects of vitamin D on
beta-cell function and glucose homeostasis. We found no association between 25(OH)D3 levels
and peripheral insulin sensitivity, HOMA-IR, IGT and type 2 diabetes. Overall, the results
could not support an association between low vitamin D status and risk of type 2 diabetes in
Greenland and emphasize the need to elucidate a causal relationship between vitamin D and
glucose intolerance.
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